locks. quarter E Third Earnings and Webcast for This Eloxx's an XXXX welcome Quarter you to excellent and Thank Barbara Conference Call. was
of the chief Tom our In team addition Haggerty to advancing appointment scientific officer. also clinical our Dr. medical leadership We've and with the programs. strengthened is
to from Schering consulted of him and us join drug team. of an brings from Merck. Tom's pleased year, companies Board our most have development like Tom established plough Certified nephrologist roles is and for past we're leadership R&D executive record and successful senior the with been track a
progress Today cystic and our clinic system fibrosis two houses. and will on an with the update clinical provide in our phase programs
point with quarters. and a have cadence haberdashery as our upcoming important progressed through moment, system progress trial will a first of Williams our in gnosis guided where we clinical data observations we've observations, you has move the steady to we additional the and updates As and share a we doctors had will
Eloxx HIT-CF presentations at Just American the hold X an full week ELX-XX. other overall potential favorable about of Fibrosis strategic made of engage study with the with subcutaneous opportunity an meet team scientific ELX-XX and Conference We scientific Cystic the community which emerging meeting the this results and North our profile partners. MAD tolerability past had reinforced including investigators' to to
level of and our remarkable. has The trials; where and we interest at for sites II expressed of quarter. support cystic two the program Phase Israel open sites we multiple have quite our in and investigators clinical sites consists expect enrolling today patients for program this really in European Europe one open fibrosis Israel Currently been to
II Phase open open well. trial States second in trial Boston we're focuses clinical and the this Our expecting U.S. sites on Hospital is where United to as additional Children's quarter today sites
has been U.S. possible Cystic the and provided the Development our Our support made Therapeutic by the expansion Foundation part fibrosis cystic the of Network. in to programs by Fibrosis
fully period cystic fibrosis interest there first of the our expressed will quarter that these enrolled patients XXXX. and We have mean the available of in will our aware in participating during sites trials are are who clinical extended trials that be opening
changing line XXXX. guidance cystic As for half a data to our we're in first the result fibrosis of top
cystinosis for escalates doses the report patient the I'm we've that cystinosis Phase program track in three population. through this ELX-XX observed each pleased report does line to II program we're in top The program. to already on and activity data study this our For quarter meaningful patient in
safety committee and we final review we're patients the the with have third and evaluate dose each doses now cohort level next are dose the at To to first the escalated After first treatment tolerability after safe by second the higher dosing and date dose. safety review and meets patients before to completed successful the in committee level. review the
principal this investigators final to panel this very measure We're quarter. been cell levels in scientific that experts Upon reporting dose before as discuss the report the proved data and with indication. in has and encouraged of the for we third are white preliminary the of efficacy and and as seeing well-tolerated data top pleased completion of significant clinical will reductions ELX-XX the showed data we the already drugs cysteine primary blood later well our of line our
Later our completed our cystinosis to of the Week preclinical to will and on present and new data participating be team renal data disorders. supporting Eloxx of this activity for additional week kidney in and study ELX-XX share studies other impairment Kidney
continued that our we quarter important in team production protein can to advance level. ophthalmology when intravitreally milestone proof-of-concept demonstrating injected the the compounds During ERSG in at animal as an achieved eye our an restore work our
retinal programs fans other indications, screening advancing other of for luck the XO cells. an molecules el of evaluate or Our novel advance or in the disorders IY, epithelial from evaluate screening Usher work primary syndrome our continue pigment photoreceptors dyskinesia such to include to RERSG new diseases ciliary to or opportunities to and as library to
support, regard into kidney high polycystic encouraging a our system nonsense results where disease, our expanding as that mutation a the such ongoing the diseases study, dominant prevalence of gnosis believe there's and we research patients. autism, And kidney from
there's level clinical We expand our programs. scientific, We most advanced therapies the and communities business strategic interest mutations high to great and relationships company footprint our in enthusiasm business in new pursuing for accelerate developing engaged actively tackling our and are the challenges remain the therapeutic of progress. and nonsense of for a
in ended quarter cash We XXXX million and equivalents. second cash XX.X the of
of XXXX. and into advance We are cystic for programs library molecules advance our top indications programs to data deliver our in into cystinosis fibrosis and clinical screening line well funded additional and the ELX-XX
mission Our them of talented to need medicines to and is safe effective and who committed possible. rapidly patients as highly bringing experienced as our team
on who'll I'd you with turn provide the Dr. an to II Greg Operating like Chief programs. Williams over our update Officer clinical now Phase to call our
